eClinical Technology and Industy News

Health Canada Authorizes Moderna’s COVID-19 Vaccine in Young Children (6 Months-5 Years)

Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults

Excerpt from the Press Release:

CAMBRIDGE, MA / ACCESSWIRE / July 14, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of Moderna’s mRNA COVID-19 vaccine, SPIKEVAX™, in a two-dose series of 25 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. Until now, children under 5 were the only age group not yet eligible in Canada for vaccination against COVID-19. The two-dose primary series of SPIKEVAX for children in this age group is completed in one month, the same primary dosing schedule as adults, adolescents, and children over 5 years of age.

“Since the pandemic began, we have worked with a deep sense of responsibility to deliver on the promise of mRNA science for Canadians,” said Patricia Gauthier, President and General Manager, Moderna Canada. “This decision from Health Canada confirms the effectiveness and safety of Moderna’s vaccine in this final and important age group. With this announcement, parents and caregivers now have an option to protect these very young children, a group at high risk of infection and where additional health prevention measures like wearing masks may not always be feasible.”

Positive interim results from the Phase 2/3 KidCOVE study, announced on March 23, 2022, showed a robust neutralizing antibody response in the 6-month to 5 years of age group after a two-dose primary series of mRNA-1273, along with a favorable safety profile. The antibody titers in the pre-specified 6 month to 23 month and 2 years to 5 years of age sub-groups met the statistical criteria for similarity to the adults in the COVE study, which satisfied the primary objective of the study.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?